• 성균관대학교 의학박사
• 성균관대학교 의학석사
• 성균관대학교 의과대학 졸업

• 2025-현재  | 이대서울병원 신경과 임상부교수
• 2022-2025  | 순천향대학교 부속 천안병원 신경과 부교수
• 2022-2023  | Neuroimmunology Clinic and Research lab, Department of Neurology, Massachusetts General Hospital/Harvard Medical School 연수
• 2017-2021  | 순천향대학교 부속 천안병원 신경과 조교수
• 2014-2017  | 삼성서울병원 신경과 전임의
• 2011  | Department of Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine 단기연수
• 2007-2011  | 삼성서울병원 신경과 전공의 수료

• 2025 | 대한신경면역학회 우수포스터상
• 2024 | 대한뇌염/뇌염증학회 우수논문상

• 2025-현재  | 대한신경근육질환학회 학술위원
• 2024-현재  | 대한신경과학회 진료지침위원
• 2024-현재  | ACN학술지 편집위원
• 2022-현재  | 대한신경면역학회 기획이사
• 2020-현재  | 대한신경면역학회 학술위원
• 2020-현재  | 대한신경면역학회 홍보위원
• 2017-현재  | 대한임상신경생리학회 교육위원
• 현재  | 대한신경과학회 정회원
• 현재  | 대한신경면역학회 정회원
• 현재  | 대한신경근육질환학회 정회원
• 현재  | 대한임상신경생리학회 정회원

•  Genetic susceptibility of human leukocyte antigen alleles in chronic inflammatory demyelinating polyneuropathy in Korean patients: Short title: HLA alleles and CIDP in Korea.  BMC Neurology. 2025-07. 
•  Comparison of treatment efficacy and cost-effectiveness of rituximab and oral agents among patients with neuromyelitis optica spectrum disorders: a population-based cohort study.  Therapeutic Advances in Neurological Disorders. 2025-04. 
•  Evaluating Rituximab Failure Rates in Neuromyelitis Optica Spectrum Disorder: A Nationwide Real-World Study From South Korea.  Journal of Clinical Neurology. 2025-02. 
•  Mortality in severe serious adverse events following heterologous and homologous prime-boost vaccination strategies for SARS-CoV-2: A retrospective cohort study.  PLoS ONE. 2025-03. 
•  Clinical usefulness of a cell-based assay for detecting myelin oligodendrocyte glycoprotein antibodies in central nervous system inflammatory disorders.  Annals of Laboratory Medicine. 2025-01. 
•  Deciphering deaths associated with severe serious adverse events following SARS-CoV-2 vaccination: A retrospective cohort study.  Vaccine: X. 2024-01. 
•  Clinical and laboratory findings in scrub typhus associated Guillain‐Barré syndrome in South Korea.  Journal of the Peripheral Nervous System. 2024-01. 
•  Anti-aquaporin-4 immune complex stimulates complement-dependent Th17 cytokine release in neuromyelitis optica spectrum disorders.  Scientific Reports. 2024-02. 
•  Evaluation of SARS-CoV-2 Vaccine-Induced Antibody Responses in Patients with Neuroimmunological Disorders: A Real-World Experience.  Diagnostics. 2024-02. 
•  Differentiated pattern of complement system activation between MOG-IgG-associated disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder.  Frontiers in Immunology. 2024-03. 
•  Establishment of a registry of clinical data and bioresources for rare nervous system diseases.  Osong Public Health and Research Persptectives. 2024-04. 
•  Sleep and neuroimmunology: a narrative review.  Encephalitis. 2024-06. 
•  Time to Treat First Acute Attack of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.  JAMA Neurology. 2024-10. 
•  Potential prognostic value of rheumatoid factor in anti-aquaporin 4-immunoglobin G-positive neuromyelitis optica spectrum disorders.  Journal of the Neurological Sciences. 2024-11. 
•  Viral Etiology of Aseptic Meningitis and Clinical Prediction of Herpes Simplex Virus Type 2 Meningitis.  Journal of Personalized Medicine. 2024-09. 
•  Quality of life in patients with myelin oligodendrocyte glycoprotein antibody associated disease compared to patients with AQP4-IgG positive neuromyelitis optica spectrum disorders: A Korean multicenter study.  Multiple Sclerosis and Related Disorders. 2024-11. 

• [파이낸셜뉴스] "왜 꼭 오후에만?"…시간대 따라 힘 빠지는 근육의 비밀 2026-10-18